<DOC>
	<DOCNO>NCT01916382</DOCNO>
	<brief_summary>This proposal develop orphan designate drug , nitisinone , treatment rare Mendelian disease , Alkaptonuria ( AKU ) . Thanks exist successful fundamental clinical research ( cell model , animal model , natural history study ) , ready final stage clinical development nitisinone AKU : phase 3 clinical trial prove efficacy . The result DevelopAKUre allow u make case European Medicines Agency market authorisation nitisinone AKU , thereby contribute goal International Rare Diseases Research Consortium develop 200 new therapy 2020 .</brief_summary>
	<brief_title>Suitability Nitisinone Alkaptonuria 2</brief_title>
	<detailed_description />
	<mesh_term>Alkaptonuria</mesh_term>
	<mesh_term>Ochronosis</mesh_term>
	<mesh_term>Nitisinone</mesh_term>
	<criteria>A patient must fulfil follow criterion order include study : 1 . Diagnosis AKU Any Clinical manifestation AKU , clinical ochronosis chronic back/joint pain . 3 . Age â‰¥25 year . 4 . Willing able visit investigational site study visit . 5 . Signed write informed consent give . The presence follow exclude patient inclusion study : 1 . Currently pregnant lactating . 2 . Female patient childbearing potential use reliable method contraception . 3 . Known allergy nitisinone constituent investigational product . 4 . Current malignancy . 5 . Uncontrolled hypertension ( blood pressure great 180 mmHg systolic great 95 mmHg diastolic ) . 6 . Unstable cardiovascular disease . 7 . Serum potassium &lt; 3.0 mmol/L . 8. eGFR &lt; 60 mL/min . 9 . ALT &gt; 1.5 x upper limit normal . 10 . Haemoglobin &lt; 10.0 g/dL . 11 . Platelets &lt; 100 x 109/L . 12 . Total white blood count &lt; 3.0 x 109/L neutrophil count &lt; 1.5 x 109/L . 13 . History alcohol drug abuse . 14 . Participation another clinical study within 3 month randomization . 15 . Treatment nitisinone within 60 day randomization . 16 . Psychiatric somatic illness interferes compliance communication health care personnel . 17 . Foreseeable inability cooperate give instruction study procedure . 18 . Any medical condition opinion investigator make patient unsuitable inclusion .</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Alkaptonuria , nitisinone , Ochronosis , Homogentisic acid</keyword>
</DOC>